St. Jude Malaysia 483 Cites Cleanroom, Training Concerns
St. Jude Medical’s Penang, Malaysia, plant received a seven-observation Form 483 at the conclusion of a May 2011 CDRH inspection.
The 483 cites multiple concerns with environmental control procedures followed in the facility’s cleanrooms. For example, dust had built up on cleanroom workbenches, and the facility manager in charge of cleaning the cleanrooms violated sterility by walking across a “non-clean” area in his shoe coverings before entering the cleanroom.
In addition, the 483 states employees in charge of assembly, packaging and quality control of Accent pacemakers and Tendril 2008 leads “are not adequately trained in the performance of their job functions.” The 483 also states that multiple processes for heart leads were not adequately validated because they could not be fully verified through subsequent testing.
The facility’s supplier control requirements were found inadequate because at least one crucial component was marked as “non-critical.” Management review procedures did not refer to supplier evaluation and assessments, the inspectors found.
“We have received the Establishment Inspection Report from the FDA indicating the 483 observations from the May 2011 FDA inspection of the Penang, Malaysia facility have been resolved,” St. Jude spokeswoman Amy Jo Meyer said. “A subsequent inspection at the Penang facility was performed in 2012 without a 483 being issued.”
Do your employees know what to keep sterile? What about correct procedures and validation processes? Form 483s are the most detailed records available of an inspection, and for that reason they are the best source of information about what happens during FDA inspections. In truth, 483s are like gold waiting to be mined and we at FDAnews have collected them for you.
With a subscription to 483sOnline.com, you can search by the name of the company that received the 483, by the date of the inspection, and by inspector and region. And the 483s are ready for you to download instantly. You even get a weekly email notice of the new 483s we’ve added, so you’re sure never to miss a thing. Don’t delay, subscribe today!
Come for this valuable opportunity to hear FDA officials discuss regulatory plans and objectives — and ask questions you need answered; learn from device industry experts, consultants and other experts with actionable tips and strategies you can take straight back to the office; and network with other professionals who understand your challenges; share war stories and insights over a drink. Register Today.Read More
The FDA's new enforcement plan makes one thing clear: Developing a successful CAPA program has never been more important. But creating an FDA-proof CAPA isn’t easy. If only you could pick the brain of someone who is coping successfully with CAPA — the best and the brightest, an industry leader who has devised programs, procedures and solutions that have put companies out in front with the FDA. Well, you can. Register today.Read More
The FDA’s cadre of freshly trained inspectors — many of whom come directly from industry — and increased focus on specialized inspections are making it harder than ever to predict the outcome of your next FDA inspection. Unless, of course, you have Surviving an FDA Inspection at your fingertips. If you could spend less than $400 to get your drug manufacturing facility fully prepared to face a tough inspection by the FDA, would you even hesitate? ... Of course not!